Zavain Dar - Apr 1, 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Apr 1, 2024
Transactions value $
$0
Form type
4
Date filed
4/3/2024, 05:43 PM
Previous filing
Jan 4, 2024
Next filing
Jun 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +1.47K +1.67% $0.00 89.1K Apr 1, 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were issued pursuant to the Issuer's Outside Director Compensation Policy.
F2 Includes a total of 32,373 shares received pursuant to a pro-rata distribution from Lux Ventures, of which the Reporting Person was a limited partner. The acquisition of such shares was exempt pursuant to Rule 16a-9 and was inadvertently excluded from the total amount of shares held on the Reporting Person's Forms 4 since July 12, 2023.